Search

Chudi O Ndubaku

from Oakland, CA
Age ~44
Get Report
Also known as:
Chudi Te Ndubaku, Chudi U, Chudi Y, I U
Phone and address:
6031 Chabolyn Ter, Oakland, CA 94618
Related to:
Sheyenne T Williams, 31Jamal SankeyUgo NdubakuOllie AndersonTimothy J Sankey, 70
Connected to:
Melissa K Ndubi, 45Chioma A Ndubisi, 43Chioma M Ndubuaku, 68Christopher U Ndubueze, 39Christian U Ndubuisi, 49Obinna S Ndubuisi, 51Cecilia Nduka, 39Charles O Ndukwe, 45Ere Ndukwe, 46Helen U Ndukwe, 73

Chudi Ndubaku Phones & Addresses

  • 6031 Chabolyn Ter, Oakland, CA 94618
  • 1050 Mississippi St, San Francisco, CA 94107 (415) 678-5019
  • 1050 Mississippi St #3, San Francisco, CA 94107 (415) 678-5019
  • 457 Vermont St, San Francisco, CA 94107
  • Hawthorne, CA
  • Somerville, MA
  • West Covina, CA
  • Berkeley, CA
  • Rancho Palos Verdes, CA

Education

Degree: Graduate or professional degree

Resumes

Resumes

Chudi Ndubaku Photo 1

Vp, Head Of Drug Discovery

View page
Location:
6031 Chabolyn Ter, Oakland, CA 94618
Industry:
Biotechnology
Work:
Genentech since Sep 2006
Scientist, Medicinal Chemistry
MIT Aug 2001 - Jul 2006
Graduate Research Assistant
University of California Jan 1999 - Jan 2001
Undergraduate Research Assistant
Agouron Pharmaceuticals Jun 1999 - Aug 1999
Research Intern
Education:
Massachusetts Institute of Technology 2001 - 2006
Ph.D, Organic Chemistry University of California, Berkeley 1997 - 2001
B.S, Chemistry
Skills:
Medicinal Chemistry
Drug Discovery
Chemistry
Organic Synthesis
Organic Chemistry
Small Molecules
Biotechnology
Drug Design
Nmr
Purification
Molecular Biology
Biochemistry
Life Sciences
Spectroscopy
Pharmacokinetics
Protein Chemistry
Languages:
English
Chudi Ndubaku Photo 2

Chudi Ndubaku

View page

Publications

Us Patents

Heterocyclic Compounds And Methods Of Use

View page
US Patent:
8232273, Jul 31, 2012
Filed:
Dec 17, 2009
Appl. No.:
12/641141
Inventors:
Jonathan Bayldon Baell - Bundoora, AU
Chinh Thien Bui - Balwyn North, AU
Peter Colman - East Melbourne, AU
Peter Czabotar - Melbourne, AU
Danette A. Dudley - Pacifica CA, US
Wayne J. Fairbrother - Burlingame CA, US
John A. Flygare - Burlingame CA, US
Guillaume Laurent Lessene - Coburg, AU
Chudi Ndubaku - San Francisco CA, US
George Nikolakopoulos - Thomastown, AU
Brad Edmund Sleebs - Reservoir, AU
Brian John Smith - Sunbury, AU
Keith Geoffrey Watson - Surry Hills, AU
Steven W. Elmore - Northbrook IL, US
Lisa A. Hasvold - Grayslake IL, US
Andrew M. Petros - Mundelein IL, US
Andrew J. Souers - Evanston IL, US
Zhi-Fu Tao - Gurnee IL, US
Le Wang - Vernon Hills IL, US
Xilu Wang - Grayslake IL, US
Kurt Deshayes - San Francisco CA, US
Assignee:
Genentech, Inc. - South San Francisco CA
Abbott Laboratories - Abbott Park IL
The Walter and Eliza Hall Institute of Medical Research - Victoria
International Classification:
A61K 31/5377
C07D 413/14
US Classification:
5142338, 544111
Abstract:
In one aspect, the present invention provides for a compound of Formula I.

Benzoxazepin P13K Inhibitor Compounds And Methods Of Use

View page
US Patent:
8242104, Aug 14, 2012
Filed:
Sep 27, 2010
Appl. No.:
12/890812
Inventors:
Nicole Blaquiere - South San Francisco CA, US
Steven Do - South San Francisco CA, US
Danette Dudley - South San Francisco CA, US
Adrian Folkes - Basel, CH
Robert Heald - Harlow, GB
Timothy Heffron - South San Francisco CA, US
Mark Jones - Harlow, GB
Aleksandr Kolesnikov - South San Francisco CA, US
Chudi Ndubaku - South San Francisco CA, US
Alan G. Olivero - South San Francisco CA, US
Stephen Price - Harlow, GB
Steven Staben - South San Francisco CA, US
Lan Wang - South San Francisco CA, US
Assignee:
F. Hoffman-La Roche AG - Basel
International Classification:
A61K 31/553
C07D 498/04
C07D 498/14
US Classification:
5142111, 51421112, 540548
Abstract:
Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Zis CRor N; Zis CRor N; Zis CRor N; Zis CRor N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Benzoxepin Pi3K Inhibitor Compounds And Methods Of Use

View page
US Patent:
8263633, Sep 11, 2012
Filed:
Sep 27, 2010
Appl. No.:
12/890810
Inventors:
Nicole Blaquiere - South San Francisco CA, US
Steven Do - South San Francisco CA, US
Danette Dudley - South San Francisco CA, US
Adrian Folkes - Basel, CH
Richard Goldsmith - South San Francisco CA, US
Robert Heald - Harlow, GB
Timothy Heffron - South San Francisco CA, US
Aleksandr Kolesnikov - South San Francisco CA, US
Chudi Ndubaku - South San Francisco CA, US
Alan G. Olivero - South San Francisco CA, US
Stephen Price - Harlow, GB
Steven Staben - South San Francisco CA, US
BinQing Wei - South San Francisco CA, US
Assignee:
F. Hoffman-La Roche AG
International Classification:
A61K 31/41
C07D 249/14
US Classification:
514383, 5482655
Abstract:
Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Zis CRor N; Zis CRor N; Zis CRor N; Zis CRor N; and where (i) Xis N and Xis S, (ii) Xis S and Xis N, (iii) Xis CRand Xis S, (iv) Xis S and Xis CR; (v) Xis NRand Xis N, (vi) Xis N and Xis NR, (vii) Xis CRand Xis O, (viii) Xis O and Xis CR, (ix) Xis CRand Xis C(R), (x) Xis C(R)and Xis CR; (xi) Xis N and Xis O, or (xii) Xis O and Xis N, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Benzoxazepin Pi3K Inhibitor Compounds And Methods Of Use

View page
US Patent:
8343955, Jan 1, 2013
Filed:
May 22, 2012
Appl. No.:
13/477587
Inventors:
Nicole Blaquiere - South San Francisco CA, US
Steven Do - South San Francisco CA, US
Danette Dudley - South San Francisco CA, US
Adrian Folkes - Basel, CH
Robert Heald - Harlow, GB
Timothy Heffron - South San Francisco CA, US
Mark Jones - Harlow, GB
Aleksandr Kolesnikov - South San Francisco CA, US
Chudi Ndubaku - South San Francisco CA, US
Alan G. Olivero - South San Francisco CA, US
Stephen Price - Harlow, GB
Steven Staben - South San Francisco CA, US
Lan Wang - South San Francisco CA, US
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
A61K 31/553
US Classification:
5142111
Abstract:
Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Zis CRor N; Zis CRor N; Zis CRor N; Zis CRor N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Compounds And Methods Of Use

View page
US Patent:
8518970, Aug 27, 2013
Filed:
Jan 10, 2012
Appl. No.:
13/347364
Inventors:
Jonathan Bayldon Baell - Bundoora, AU
Chinh Thien Bui - Balwyn North, AU
Peter Colman - East Melbourne, AU
Danette A. Dudley - Pacifica CA, US
Wayne J. Fairbrother - Burlingame CA, US
John A. Flygare - Burlingame CA, US
Guillaume Laurent Lessene - Coburg, AU
Chudi Ndubaku - San Francisco CA, US
George Nikolakopoulos - Thomastown, AU
Carl Steven Rye - Epsom, GB
Brad Edmund Sleebs - Reservoir, AU
Brian John Smith - Sunbury, AU
Keith Geoffrey Watson - Surry Hills, AU
Steven W. Elmore - Northbrook IL, US
Andrew M. Petros - Mundelein IL, US
Andrew J. Souers - Evanston IL, US
Peter Czabotar - Melbourne, AU
Assignee:
AbbVie Inc. - North Chicago IL
Genentech, Inc. - South San Francisco CA
The Walter and Eliza Hall Institute of Medical Research - Parkville, Victoria
International Classification:
C07D 417/14
A61K 31/5377
A61K 31/538
A61K 31/496
A61K 31/498
A61K 31/4709
US Classification:
514314, 514249, 5142305, 5142338, 51425306, 51426621, 514367, 51421301, 5142621, 51425505, 544235, 544363, 544128, 544353, 544284, 544262, 544405, 548159, 540593, 546165
Abstract:
In one aspect, the present invention provides for a compound of Formula I.

Benzoxazepin Pi3K Inhibitor Compounds And Methods Of Use

View page
US Patent:
8586574, Nov 19, 2013
Filed:
Nov 20, 2012
Appl. No.:
13/681763
Inventors:
Steven Do - San Jose CA, US
Danette Dudley - Pacifica CA, US
Adrian Folkes - Slough, GB
Robert Heald - Harlow, GB
Timothy Heffron - Burlingame CA, US
Mark Jones - Harlow, GB
Aleksandr Kolesnikov - San Francisco CA, US
Chudi Ndubaku - San Francisco CA, US
Alan G. Olivero - Half Moon Bay CA, US
Stephen Price - Harlow, GB
Steven Staben - San Francisco CA, US
Lan Wang - Foster City CA, US
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
A61K 31/553
C07D 498/04
C07D 498/14
US Classification:
5142111, 51421112, 540548
Abstract:
Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Zis CRor N; Zis CRor N; Zis CRor N; Zis CRor N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Compounds And Methods Of Use

View page
US Patent:
20100190782, Jul 29, 2010
Filed:
Dec 17, 2009
Appl. No.:
12/641063
Inventors:
Jonathan Bayldon Baell - Bundoora, AU
Chinh Thien Bui - Balwyn North, AU
Peter Colman - East Melbourne, AU
Danette A. Dudley - Pacifica CA, US
Wayne J. Fairbrother - Burlingame CA, US
John A. Flygare - Burlingame CA, US
Guillaume Laurent Lessene - Coburg, AU
Chudi Ndubaku - San Francisco CA, US
George Nikolakopoulos - Thomastown, AU
Carl Steven Rye - Beaconsfield, GB
Brad Edmund Sleebs - Reservoir, AU
Brian John Smith - Sunbury, AU
Keith Geoffrey Watson - Surry Hills, AU
Steven W. Elmore - Northbrook IL, US
Andrew M. Petros - Mundelein IL, US
Andrew J. Souers - Evanston IL, US
International Classification:
A61K 31/536
C07D 417/14
A61K 31/4709
C07D 487/04
A61K 31/519
A61K 31/502
A61K 31/428
A61K 31/5377
A61P 35/02
A61P 35/00
A61P 7/02
A61P 9/00
US Classification:
5142305, 546165, 514314, 544105, 544262, 5142621, 544353, 514249, 548159, 514367, 544128, 5142338
Abstract:
In one aspect, the present invention provides for a compound of Formula Iin which in Formula I, the variables X, X, X, X, R, B, L, E, A and the subscript n are as defined herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xproteins.

Inhibitors Of Iap

View page
US Patent:
20110046066, Feb 24, 2011
Filed:
Jan 9, 2009
Appl. No.:
12/812292
Inventors:
Chudi Ndubaku - San Francisco CA, US
John A. Flygare - Burlingame CA, US
Frederick Cohen - San Francisco CA, US
Assignee:
GENENTECH, INC. - SOUTH SAN FRANCISCO CA
International Classification:
A61K 38/06
C07K 5/083
C07K 5/062
C12N 5/071
A61K 38/05
A61P 35/00
US Classification:
514 189, 530331, 548204, 435375, 514 193
Abstract:
The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula (I), and G, X, X, R, R, R, R, R′, R, R, R, and Rare as described herein.
Control profile
Chudi O Ndubaku from Oakland, CA, age ~44 Get Report